Volume 20, Number 5—May 2014
Research
Bovine Leukemia Virus DNA in Human Breast Tissue
Table 5
Sample code | Sample pathology | Patient age, y | BLV genome regions |
||||||
---|---|---|---|---|---|---|---|---|---|
L-PCR |
IS-PCR |
||||||||
LTR | gag | pol | env | tax | tax | ||||
143 | Malignant | 63 | – | – | – | – | – | – | |
0253 | Malignant | 47 | + | – | – | – | + | + | |
010 | Malignant | 48 | + | – | – | – | + | + | |
236 | Nonmalignant | 54 | + | + | – | + | + | + | |
23803 | Nonmalignant | 50 | + | + | – | + | + | + | |
20874 | Nonmalignant | 53 | + | + | + | + | + | + |
*BLV, bovine leukemia virus; L-PCR, nested liquid-phase PCR; IS-PCR, nested in situ PCR; LTR, long terminal repeat (promoter region); gag, group-specific antigen (capsid region); pol, polymerase (reverse transcription); env, envelope; tax, transactivating region of the X gene.
1Current affiliation: Texas A&M Health Science Center College of Medicine, College Station, Texas, USA.
Page created: April 16, 2014
Page updated: April 16, 2014
Page reviewed: April 16, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.